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Abstract: Aldosterone (Aldo), when overproduced, is a cardiotoxic hormone underlying heart failure
and hypertension. Aldo exerts damaging effects via the mineralocorticoid receptor (MR) but also
activates the antiapoptotic G protein-coupled estrogen receptor (GPER) in the heart. G protein-coupled
receptor (GPCR)-kinase (GRK)-2 and -5 are the most abundant cardiac GRKs and phosphorylate
GPCRs as well as non-GPCR substrates. Herein, we investigated whether they phosphorylate
and regulate cardiac MR and GPER. To this end, we used the cardiomyocyte cell line H9c2
and adult rat ventricular myocytes (ARVMs), in which we manipulated GRK5 protein levels
via clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and GRK2 activity
via pharmacological inhibition. We report that GRK5 phosphorylates and inhibits the cardiac MR
whereas GRK2 phosphorylates and desensitizes GPER. In H9c2 cardiomyocytes, GRK5 interacts
with and phosphorylates the MR upon β2 -adrenergic receptor (AR) activation. In contrast, GRK2
opposes agonist-activated GPER signaling. Importantly, GRK5-dependent MR phosphorylation of
the MR inhibits transcriptional activity, since aldosterone-induced gene transcription is markedly
suppressed in GRK5-overexpressing cardiomyocytes. Conversely, GRK5 gene deletion augments
cardiac MR transcriptional activity. β2 AR-stimulated GRK5 phosphorylates and inhibits the MR
also in ARVMs. Additionally, GRK5 is necessary for the protective effects of the MR antagonist
drug eplerenone against Aldo-induced apoptosis and oxidative stress in ARVMs. In conclusion,
GRK5 blocks the cardiotoxic MR-dependent effects of Aldo in the heart, whereas GRK2 may hinder
beneficial effects of Aldo through GPER. Thus, cardiac GRK5 stimulation (e.g., via β2 AR activation)
might be of therapeutic value for heart disease treatment via boosting the efficacy of MR antagonists
against Aldo-mediated cardiac injury.
Keywords: aldosterone; cardiac myocyte; G protein-coupled receptor kinase; G protein-coupled
estrogen receptor; mineralocorticoid receptor; signal transduction
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1. Introduction
Aldosterone (Aldo) is among the hormones for which levels are elevated and contributes
significantly to the pathogenesis and morbidity/mortality of heart disease, including hypertension and
chronic heart failure (CHF) [1]. Most of its cardiotoxic effects are mediated by the mineralocorticoid
receptor (MR), a transcription factor expressed in various tissues including the heart [2]. However,
Aldo exerts MR-independent (“non-genomic”) actions, a great deal of which are through activation of
the G protein-coupled receptor 30 (GPR30) or G protein-coupled estrogen receptor (GPER), a plasma
membrane G protein-coupled receptor (GPCR) [3]. Most of the pathophysiological effects of Aldo in
the heart and vessels, which can cause essential hypertension and trigger cardiac hypertrophy, fibrosis,
and adverse remodeling, are thought to result from MR activation, whereas several studies suggest that
GPER activation may actually be beneficial in the myocardium, partly due to activation of antiapoptotic
mediators, such as Epidermal Growth Factor Receptor (EGFR) and extracellular signal-regulated kinase
(ERK)1/2 [2–7]).
Most GPCRs undergo functional desensitization due to phosphorylation by GPCR-kinases (GRKs),
a Ser/Thr protein kinase family, followed by binding of βarrestins which uncouple the receptor from its
cognate G proteins [8]. GRK2 and -5 are the most abundant GRKs in the heart and are also known to
phosphorylate non-GPCR substrates [9,10]. The MR is known to be phosphorylated at various Ser/Thr
residues, including Ser-843 of the ligand-binding domain and Ser-601 of the N-terminal domain [11].
These phosphorylating events occur in the cytoplasm, and some of them result in MR inhibition either
via direct repression of transcriptional activity (e.g., the Ser-843 phosphorylation) or via cytosolic
retention, i.e., blockade of nuclear translocation (e.g., the Ser-601 phosphorylation) [11]. Herein, we
sought to investigate the potential involvement of GRK2 and -5 in the regulation of cardiac Aldo
signaling via the MR and/or GPER.
2. Results
2.1. β2 AR-Activated GRK5 but Not GRK2 and Interacts with the MR in H9c2 Cardiomyocytes
Via co-immunoprecipitation (co-IP) experiments in cultured H9c2 cardiomyocytes,
which endogenously express both β1 - and β2 -adrenergic receptors (ARs) [12] as well as the MR and
GPER [13,14], we uncovered that GRK5 interacts with the MR constitutively and that this interaction
is significantly boosted by β2 AR activation with formoterol (Figure 1A,B). Of note, the non-subtype
selective βAR agonist isoproterenol did not affect appreciably the GRK5–MR interaction (Figure 1A,B),
suggesting that the β1 AR might somehow compete with and offset the β2 AR-mediated induction of
this interaction in H9c2 cardiomyocytes. In contrast to GRK5, no GRK2 interaction with the MR could
be detected under any treatment conditions (including constitutively, i.e., no cell treatment) in H9c2
cardiomyocytes (Figure 1A).
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luciferase gene under the influence of the MR gene (NR3C2) promoter, we found that Aldo-dependent
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the effects of GRK5 on Aldo signaling also in cultured adult rat ventricular myocytes (ARVMs),
a bona fide cardiomyocyte cell system even more physiologically relevant than H9c2 myocytes. We
also tested the effects of GRK5 in ARVMs in the presence or absence of the known MR antagonist
(MRA) drug eplerenone [17]. As shown in Figure 4A,B, eplerenone was only partially effective at
blocking Aldo-induced apoptosis in control ARVMs. In GRK5-overexpressing ARVMs however
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2.5. MR Inhibition by GRK5 in ARVMs Is β2AR-Inducible
Our results from H9c2 cardiomyocytes indicated that β2AR activation augments the interaction
between GRK5 and the cardiac MR. On the other hand, GRK5 is activated by the β2AR (itself a
substrate of this kinase) [18]. Therefore, we sought to interrogate further the role of the β2AR in GRK5dependent
inhibition in cultured ARVMs. As shown in Figure 5A,B, β2AR-selective activation7 of 17
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To confirm that β2 AR-induced, GRK5-mediated MR phosphorylation leads to inhibition of
transcriptional activity also in ARVMs, we measured Aldo-dependent mRNA induction of the
plasminogen activator inhibitor (PAI)-1 gene, one of the immediate/early Aldo-inducible genes in
target tissues [20,21]. Indeed, β2 AR activation with salbutamol completely blocked Aldo-induced
PAI-1 mRNA expression in ARVMs (Figure 5E). Importantly, this inhibitory effect of the β2 AR was
GRK5-dependent, since salbutamol had no effect on Aldo-induced PAI-1 mRNA upregulation in
ARVMs transfected with the kinase-dead GRK5 mutant (Figure 5E). Taken together, these results
strongly suggest that the cardiac β2 AR (but not the β1 AR) induces GRK5-mediated phosphorylation
of the cardiac MR, thereby inhibiting the latter‘s transcriptional activity.
2.6. Cardiac β2 AR-Stimulated GRK5-MR Interaction Is Cytoplasmic and Ca2+ -Calmodulin (CaM)-Dependent
To delineate the signaling mechanism(s) underlying stimulation of GRK5-mediated
phosphorylation of the cardiac MR by the β2 AR, we first examined the subcellular localization
of the GRK5–MR interaction in H9c2 cardiac myocytes. Since both the MR and GRK5 can localize in
both the cytoplasm and the nucleus [5,22,23], one important question arising from our present findings
is which subcellular fraction these two proteins interact with each other in. To this end, we subjected
H9c2 cell lysates to subcellular fractionation and we performed co-IP experiments in cytosolic and
nuclear fraction extracts. As shown in Figure 6A, the GRK5–MR complex could be detected only in the
cytosolic fraction extracts, both in the absence and presence of Aldo. Additionally, overexpression of a
dominant negative GRK5 mutant permanently “trapped” in the nucleus due to lack of a nuclear export
sequence (∆NES-GRK5) [23] was incapable of interacting with the MR in H9c2 whole cell lysates.
Therefore, GRK5 interacts with and phosphorylates the MR in the cytoplasm, causing retention of the
Aldo–MR complex in the cytosol, i.e., blockade of the complex‘s gene transcriptional activity.
Given that GRK5 is normally plasma membrane-anchored, thanks to its constitutive interaction
with membrane phospholipids [9], an important question pertains to the mechanism of its translocation
to the cytoplasm, wherein it phosphorylates the MR. Recent studies have revealed that the ubiquitous
Ca2+ -binding protein CaM, known to inhibit GRK5 membrane localization and activity toward
GPCR phosphorylation [24], can markedly increase GRK5 activity towards non-GPCR (noncanonical)
substrates as well as can induce GRK5 translocation to the nucleus [22]. The latter process has been
reported to mediate GRK5-depedendent cardiac hypertrophy [23]. Therefore, we hypothesized that
Ca2+ signaling through CaM activation may be involved in the β2 AR-stimulated GRK5–MR interaction
in the cytosol of H9c2 cardiomyocytes. Indeed, pretreatment of cells with the phospholipase C (PLC)-β
inhibitor U73122 [25] abolished the salbutamol-enhanced (but not the basal) GRK5 interaction with
the MR in H9c2 whole lysates (Figure 6B,C). Since PLCβ activation induces Ca2+ signaling and
activates CaM via Ca2+ release from intracellular 1’, 4’, 5’-inositol trisphosphate (IP3 )-gated stores [26],
this result suggests that β2 AR-activated GRK5 translocates to the cytosol to phosphorylate the MR in a
PLCβ-Ca2+ -CaM-dependent manner.
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The MR undergoes various posttranslational modifications, such as phosphorylation, ubiquitination, etc.,
The MR undergoes various posttranslational modifications, such as phosphorylation,
which regulate its transcriptional activity and/or ligand binding specificity/affinity [11,29]. Phosphorylation of
ubiquitination, etc., which regulate its transcriptional activity and/or ligand binding
cofactors required for MR transcriptional activity plays a role as well [30]. GRKs are known to phosphorylate
specificity/affinity [11,29]. Phosphorylation of cofactors required for MR transcriptional activity plays
not only agonist-activated GPCRs in order to desensitize them but also non-GPCR substrates [9,23]. GRK2
a role as well [30]. GRKs are known to phosphorylate not only agonist-activated GPCRs in order to
and GRK5 are the most abundant isoforms in extraretinal tissues, and GRK2, cytoplasmic when inactive,
desensitize them but also non-GPCR substrates [9,23]. GRK2 and GRK5 are the most abundant
requires interaction with the free Gβγ subunits of activated G proteins for activation/membrane
isoforms in extraretinal tissues, and GRK2, cytoplasmic when inactive, requires interaction with the
translocation [9]. In contrast, GRK5 is ionically bound to cell membrane phospholipids via a highly
free Gβγ subunits of activated G proteins for activation/membrane translocation [9]. In contrast,
basic region of its C-terminus, so it is usually cell membrane-anchored [31]. Notably, the MR was
GRK5 is ionically bound to cell membrane phospholipids via a highly basic region of its C-terminus,
recently shown to promote heart failure by activating GRK2-dependent apoptosis and GRK5 nuclear
so it is usually cell membrane-anchored [31]. Notably, the MR was recently shown to promote heart
accumulation-dependent hypertrophy in transgenic mouse hearts in vivo [30]. These noncanonical,
failure by activating GRK2-dependent apoptosis and GRK5 nuclear accumulation-dependent
deleterious effects of the two GRKs were mediated by MR-induced, c-Src kinase-dependent cardiac
hypertrophy in transgenic mouse hearts in vivo [30]. These noncanonical, deleterious effects of the
angiotensin II type 1 receptor (AT1 R) transactivation [22,30].
two GRKs were mediated by MR-induced, c-Src kinase-dependent cardiac angiotensin II type 1
In the present study, we have uncovered that these two GRKs can also regulate Aldo receptor
receptor (AT1R) transactivation [22,30].
signaling in cardiac myocytes in their own right. Specifically, GRK5 (but not GRK2) phosphorylates
In the present study, we have uncovered that these two GRKs can also regulate Aldo receptor
the MR in both H9c2 cardiomyocytes and in ARVMs, inhibiting its transcriptional activity, while GRK2
signaling in cardiac myocytes in their own right. Specifically, GRK5 (but not GRK2) phosphorylates
phosphorylates and desensitizes GPER (Figure 7). Moreover, this noncanonical effect of GRK5 is
the MR in both H9c2 cardiomyocytes and in ARVMs, inhibiting its transcriptional activity, while
β2 AR-dependent. Moreover, it appears essential for the cardioprotection afforded by MRA drugs like
GRK2 phosphorylates and desensitizes GPER (Figure 7). Moreover, this noncanonical effect of GRK5
eplerenone against Aldo’s deleterious effects. Nevertheless, the precise effects of GRK5-dependent
is β2AR-dependent. Moreover, it appears essential for the cardioprotection afforded by MRA drugs
like eplerenone against Aldo’s deleterious effects. Nevertheless, the precise effects of GRK5dependent MR phosphorylation on eplerenone’s MR inhibitory efficacy warrant further investigation
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MR phosphorylation on eplerenone’s MR inhibitory efficacy warrant further investigation and will
be the focus of our future studies. In addition, identification of the exact Ser/Thr residues of the
MR phosphorylated by GRK5 is already under way in our laboratory. An important question that
arises is why GRK2 appears incapable of phosphorylating the MR as GRK5 does. This awaits further
investigation. However, GRK5 phosphorylates the MR in the cytoplasm in order to block nuclear
translocation and subsequent gene transcription activation, and GRK2, when activated, is located in
the plasma membrane [9,23]. Thus, it is tempting to speculate that the reason might be simply the
different subcellular compartmentalization of active GRK2 and the MR that prevents their interaction.
Of note, GRK5’s nuclear/genomic effects, as a class II histone deacetylase (HDAC) kinase, have been
postulated to be harmful (i.e., pro-hypertrophic) in the heart [23]. Therefore, the subcellular localization
of GRK5 seems to be of paramount importance for this kinase‘s cardiac effects: inside the nucleus,
it promotes maladaptive hypertrophy, but in the cytoplasm, it has beneficial effects via inhibition of the
MR. Cardiac MR blockade is another line of evidence for GRK5’s overall beneficial, protective role
in the myocardium. Indeed, enhanced GRK5 activity has been associated with favorable, β-blocker
treatment-like outcomes in human CHF [32] with attenuated atherosclerosis [33] and with better cardiac
function in humans/CHF patients [34]. Additionally, GRK5 has been well documented to inhibit cardiac
nuclear factor (NF)-κB, resulting in reduced myocardial inflammation [35,36]. In contrast, every cardiac
effect of GRK2 reported thus far appears deleterious for cardiac function and/or structure [8,26], and our
present study adds one more to this list: cardiac GPER desensitization.
GPER (or GPR30) is a GPCR responsible for some of the rapid (non-genomic) effects of
estrogen [4,6,7]. It is expressed in both cardiac myocytes and fibroblasts and can couple to both
Gi and Gs proteins inducing EGFR or insulin-like growth factor-1 receptor (IGF-1R) transactivation
in various tissues [4,6,7]. The precise cardiovascular effects of GPER activation in the heart and in
vessels are still under intense investigation, but the majority of the studies indicate beneficial roles
for this receptor, such as vasodilation; antiapoptosis/proliferation of vascular smooth muscle and
endothelial cells; high-salt-induced diastolic dysfunction attenuation; reduction in left ventricular filling
pressure, mass, and wall thickness; improved cardiac function; and inhibition of cardiac fibroblast
proliferation [6,7]. Therefore, the fact that GRK2 opposes the antiapoptotic GPER signaling in cardiac
cells is consistent with this kinase’s well-established role in cardiac apoptosis and may represent
another mechanism underlying the cardiotoxic effects of this kinase [23].
As far as the signaling pathway that underlies the stimulation of GRK5 by the β2 AR to
phosphorylate the cardiac MR in the cytoplasm is concerned, it is interesting to note that the β1 AR
does not seem to share this ability. In fact, it probably opposes this GRK5 effect, since isoproterenol,
which activates both β2 - and β1 ARs equipotently, does not promote GRK5–MR association (Figure 1) or
MR phosphorylation by GRK5 (Figure 5A,B). The reason for this will be the focus of future investigations.
The obvious explanation would be that the β1 AR cannot activate the PLCβ-Ca2+ -CaM pathway as
the β2 AR can and, thus, cannot induce the “shedding” of GRK5 from the cell membrane. In support
of this, a recent study reported that protein kinase A (PKA), robustly activated by the cardiac β1 AR,
inhibits β2 AR’s ability to stimulate Ca2+ -CaM signaling via ERKs and IP3 in the caveolae of atrial
myocytes [37]. It is thus quite plausible that the β1 AR antagonizes the β2 AR-induced, Ca2+ -dependent
GRK5 cytoplasmic/nuclear translocation in cardiac myocytes [22]. Of note, although it normally does
not couple to Gq proteins, the β2 AR has been reported to directly activate PLCβ, eliciting intracellular
IP3 -dependent Ca2+ mobilization/signaling [38].
4. Materials and Methods
All drugs/chemicals were from Sigma-Aldrich (St. Louis, MO, USA), except for Cmpd101
(HelloBio, Cat. #HB2840, Bristol, UK) and U73122 (MilliporeSigma, Cat. #CAS 112648-68-7, Burlington,
MA, USA).
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4.1. Cell Culture, Viruses, and Transfections
The H9c2 rat cardiomyoblast cell line was purchased from American Type Culture Collection
(Manassas, VA, USA) and cultured as previously described [12,39]. ARVMs were isolated from
adult male Wistar-Kyoto rats and cultured, as previously described [40]. H9c2 cells were used
because they are a universally accepted and widely used cell model system for signaling studies in
cardiac myocytes. Nevertheless, they are not bona fide cardiac myocytes (for instance, they do not
contract); for this reason, ARVMs, which are bona fide, fully differentiated cardiac myocytes, were also
used. Recombinant lentiviruses encoding for human wild-type full-length GRK5 or for empty vector
(control) (OriGene Technologies, Rockville, MD, USA) were propagated and purified via CsCl density
gradient ultracentrifugation, as described previously [25,39]. For CRISPR/Cas9-mediated GRK5 gene
deletion, a gRNA sequence was custom-synthesized by Sigma-Aldrich (target ID: RN0000391809,
target sequence: 5’-GTGGTTTGAATTTATGCGG-3’, predicted efficiency: 69.8, predicted specificity:
99.7) and incorporated into a lentiviral vector (Sigma-Aldrich). Along with negative control CRISPR
lentiviral particles (CNCV, Cat #CRISPR12V-1EA, Sigma-Aldrich), this lentivirus was also propagated
and purified through cesium chloride density gradient ultracentrifugation. The kinase-dead GRK5
(K215R) [19] mutant cDNA was generated using the QuikChange site-directed mutagenesis kit (Agilent
Technologies, Santa Clara, CA, USA), and proper insertion of the point mutation was verified by PCR.
The mutant cDNA was then inserted into a lentiviral vector for lentiviral particle production and
packaging (custom-made by Vigene Biosciences, Rockville, MD, USA).
4.2. Co-Immunoprecipitation (Co-IP) and Western Blotting
H9c2 or ARVM cell extracts were prepared, as described previously [39], in a 20-mM Tris pH 7.4
buffer containing 137 mM NaCl, 1% Nonidet P-40, 20% glycerol, 10 mM phenylmethylsulfonylfluoride
(PMSF), 1 mM Na3 VO4 , 10 mM NaF, 2.5 µg/mL aprotinin, and 2.5 µg/mL leupeptin. Protein
concentration was determined (Pierce BCA Protein Assay Kit, Thermo Scientific, Waltham, MA,
USA), and equal amounts of protein per sample were used for IP or western blotting. MR was
immunoprecipitated by overnight incubation of extracts with an anti-MR antibody (#ab62532; Abcam,
Cambridge, MA, USA), attached to Protein A/G-Sepharose beads (Sigma-Aldrich), while GPER
was immunoprecipitated with an anti-GPER antibody ((#ab39742; Abcam), also attached to Protein
A/G-Sepharose beads (Sigma-Aldrich). The IPs were then subjected to immunoblotting for GRK2
(sc-562; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or GRK5 (sc-565; Santa Cruz Biotechnology)
or for phosphoserine (AB1603; Millipore-Sigma) to measure the pSer content of the immunoprecipitated
MR. For the subcellular fractionation of H9c2 cells, cells were lysed using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Cat. #78833; Thermo-Scientific, Rockford, IL, USA), according
to the manufacturer’s instructions. Primary antibodies to detect tubulin (#ab56676; Abcam), as a
cytoplasmic fraction marker, and lamin A (#ab108922; Abcam), as a nuclear fraction marker, were used.
Finally, an anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (sc-25778; Santa Cruz
Biotechnology) was used to control for protein loading. All immunoblots were revealed by enhanced
chemiluminescence (ECL, Life Technologies, Grand Island, NY, USA) and visualized in the FluorChem
E Digital Darkroom (Protein Simple, San Jose, CA, USA), as described previously [39].
4.3. Luciferase Reporter Activity Assay
Luciferase reporter activity assay was performed by transfecting the cells with the LightSwitch™
luciferase reporter gene vector under the influence of the MR promoter (Active Motif, Inc., Carlsbad,
CA, USA) [41]. The measurements were done the next day with the manufacturer’s LightSwitch™
assay kit and according to its instructions.
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4.4. TUNEL and Real-Time PCR
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay to
measure apoptotic cell death was done as described [42]. Briefly, cells were fixed with 10% neutral
buffered formalin, embedded in paraffin, and sectioned at 5-µm thickness. DNA fragmentation
was detected in situ in deparaffinized sections using the ApopTag peroxidase in situ apoptosis
detection Kit (EMD Millipore) and according to manufacturer’s instructions. The total number of
nuclei was determined by manual counting of 40 ,6-diamidino-2-phenylindole (DAPI)-stained nuclei
in six random fields per section. All terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL)-positive nuclei were counted in each section. Real-time PCR for rat PAI-1
mRNA levels in total RNA isolated from ARVMs was done as described previously [39,42,43]. Briefly,
quantitative real-time PCR was performed using a MyIQ Single-Color Real-Time PCR detection system
(Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green Supermix (Bio-Rad) and 100 nM of
gene-specific oligonucleotides. Quantification of mRNA included normalization to 18s rRNA levels.
No bands were seen in control reactions in the absence of reverse transcriptase. Primer pairs used
were 5’-TTCCTCCACAGCCATTCTAGTCT-3’ and 5’-GAAAGGATCGGTCTAAAACCATCTC-3’ for
PAI-1; 50 -TCGATGCTCTTAGCTGAGTG-30 and 50 -TGATCGTCTTCGAACCTCC-30 for 18S rRNA.
4.5. Oxidative Stress Assay
To determine reactive oxygen species (ROS) production, the 20 ,70 -dichlorofluorescein diacetate
(DCFDA) dye-based assay kit from Molecular Probes (Cat. #C13293; Eugene, OR, USA) was
used, and the measurements were done according to manufacturer’s instructions and as previously
described [44]. Briefly, cell extracts were incubated with 2 µM DCFDA for 20 min and ROS production
was monitored by determining the fluorescence intensity using a fluorescent plate reader in which
excitation and emission wavelengths were set at 495 and 520 nm, respectively. The fluorescence OD
values obtained were normalized with protein determination and expressed as % of the values obtained
in vehicle (1 µM DMSO)-treated cells.
4.6. GTPγS Assay
The GTPγS assay was performed as we have previously described [45]. Briefly, cell membranes
were prepared by centrifugation and resuspension in hypotonic lysis buffer. The reaction was started by
adding an aliquot of membrane suspension to reaction buffer containing 25 mM Tris-HCl, pH 7.4, 5 mM
MgCl2 , 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol, 100 mM NaCl, 1 µM GDP,
and 2 nM [35 S]-GTPγS (from PerkinElmer, Billerica, MA, USA) with or without agonist. Reaction was
stopped with ice-cold Tris-HCl buffer, pH 7.4, followed by filtration (Whatman GF/B glass fiber filters,
MilliporeSigma) and scintillation counting. Ten µM (cold) GTPγS was used to measure nonspecific
binding. Cells were pretreated with 100 nM G1 in the presence or absence of 30 µM Cmpd101,
followed by a 100 nM G1 challenge for 15 min in order to determine agonist-induced desensitization.
4.7. Statistical Analysis
Student’s t test and one- or two-way ANOVA with Bonferroni test were used for statistical
comparisons, unless otherwise indicated. For multiple group analyses, Dunnett’s test with SAS version
9 software (Cary, NC, USA) was also used. A p value of <0.05 indicated statistical significance.
5. Conclusions
We have uncovered a new unconventional (non-GPCR) substrate for cardiac GRK5, the MR,
which results in cardioprotective effects of this kinase against Aldo. In contrast, GRK2 phosphorylates
and desensitizes cardiac GPER with potentially cardiotoxic consequences. Admittedly, the major
limitation of our study is that its findings await in vivo validation. Nevertheless, we have confirmed
this novel role for cardiac GRK5 in a bona fide cardiomyocyte cell system (ARVMs) and we have
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delineated the underlying signaling mechanism. Upon confirmation in vivo, these findings may
provide additional evidence for the emerging role of GRK5 as the GRK isoform acting as the protective
ballast against the generally deleterious GRK2 in the heart. Finally, GRK5-dependent MR inhibition
appears essential for the cardioprotection afforded by MRA drugs, like eplerenone, against Aldo. Given
the problems and limitations hampering clinical efficacy of this drug class for advanced human CHF
and other heart diseases [5], cardiac GRK5 stimulation (either directly with a small organic molecule or
indirectly via β2 AR-selective agonism) may offer a new pharmacotherapeutic avenue to augment the
cardiac benefits of Aldo inhibitor drugs.
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